Cancer detection fluorescent probes
Glycosidase-reactive fluorescent probes address the challenge of detecting mammary gland tumors and lung cancers by targeting tumor-specific glycosidase activities, enabling precise imaging and improving surgical precision.
Patent Information
- Application Number
- JP2021502655
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-28
- Filing Date
- 2020-02-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-02-28
AI Technical Summary
Existing fluorescent probes lack sensitivity and specificity in detecting malignant and benign tumors of the mammary gland, lung adenocarcinoma, and lung squamous cell carcinoma due to similar aminopeptidase activity levels between cancerous and normal tissues.
Development of glycosidase-reactive fluorescent probes that target specific glycosidase activities varying by tumor type, allowing for the detection of breast cancer, benign tumors of the mammary gland, and lung adenocarcinoma or squamous cell carcinoma, using compounds represented by general formula (I) or (II) with specific substituents and linkers (L) for imaging.
The probes enable accurate visualization and differentiation of breast cancer, benign tumors, and lung adenocarcinoma or squamous cell carcinoma by highlighting tumor-specific glycosidase activity, enhancing the efficiency of surgical resection by distinguishing between malignant and benign tissues.
Smart Images

Figure 0007595354000021 
Figure 0007595354000022 
Figure 0007595354000023
Abstract
Description
[Technical field]
[0001] The present invention relates to a fluorescent probe capable of specifically detecting cancer, more specifically, the present invention relates to a fluorescent probe capable of detecting malignant and benign tumors of the breast, lung adenocarcinoma or lung squamous cell carcinoma. [Background technology]
[0002] Methods for evaluating enzyme activity in malignant tissues can provide information about effective biomarkers for guiding cancer detection. Fluorescence-guided detection of cancer is one of the most promising approaches to improve the efficiency of partial resection surgery. The present inventors' research group has previously developed an active aminopeptidase-reactive fluorescent probe (Non-Patent Document 1) and successfully detected human breast and esophageal cancer within minutes by locally spraying the probe solution (Non-Patent Documents 2 and 3).
[0003] However, there are many malignant tumors that have not yet been detected with high sensitivity and specificity by these fluorescent probes, due to the lack of obvious differences in aminopeptidase activities between cancer and normal tissues. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Urano, Y. et al. Science Transl Med, 3, 110 (2011) [Non-Patent Document 2] Onoyama, H. et al. Sci. Rep., 6, 26399 (2016) [Non-Patent Document 3] Ueo, H. et al. Sci. Rep., 5, 12080 (2015) DISCLOSURE OF THEINVENTION [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a fluorescent probe capable of detecting malignant and benign breast tumors, lung adenocarcinoma, or lung squamous cell carcinoma. [Means for solving the problem]
[0006] The inventors focused on glycosidase activity in cancer, prepared various fluorescent probes for detecting different glycosidase activities, and used these fluorescent probes to perform comprehensive screening of glycosidase activity in human surgical specimens. As a result, they discovered that glycosidase activity varies depending on the type of tumor and that certain fluorescent probes are effective for specific imaging of tumors, thereby completing the present invention.
[0007] That is, the present invention provides: [1] A fluorescent probe for detecting breast cancer and benign breast tumors, comprising a compound represented by the following general formula (I) or a salt thereof: TIFF0007595354000001.tif52148 (in the formula, R1, if present, represents identical or different monovalent substituents present on the benzene ring; R2 and R3 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R4 and R5 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R6 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a fluorinated alkyl group having 1 to 5 carbon atoms; R7 and R8, if present, each independently represent an alkyl group or an aryl group having 1 to 6 carbon atoms; Herein, when X is an oxygen atom, R7 and R8 do not exist; X represents an oxygen atom, a silicon atom, or a carbon atom; n is an integer from 1 to 3; L is selected from any of the groups represented by the following formulas (1) to (6). TIFF0007595354000002.tif105165[2] The fluorescent probe described in [1], wherein X is an oxygen atom. [3] The fluorescent probe according to [1] or [2], wherein R6 is a fluoroalkyl group having 1 to 5 carbon atoms. [4] A fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to any one of [1] to [3] and a GGT activity detection probe. [5] A fluorescent probe for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising a compound represented by the following general formula (I) or a salt thereof: TIFF0007595354000003.tif49158 (in the formula, R1, if present, represents identical or different monovalent substituents present on the benzene ring; R2 and R3 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R4 and R5 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R6 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a fluorinated alkyl group having 1 to 5 carbon atoms; R7 and R8, if present, each independently represent an alkyl group or an aryl group having 1 to 6 carbon atoms; Herein, when X is an oxygen atom, R7 and R8 do not exist; X represents an oxygen atom, a silicon atom, or a carbon atom; n is an integer from 1 to 3; L is selected from the groups of the following formula (5) or (6): TIFF0007595354000004.tif34155[6] A fluorescent probe according to [5], wherein X is an oxygen atom. [7] The fluorescent probe according to [5] or [6], wherein R6 is a fluorinated alkyl group having 1 to 5 carbon atoms. [8] A method for detecting breast cancer and benign breast tumors, comprising: (a) applying a fluorescent probe according to any one of [1] to [4] to a clinical breast specimen; and (b) measuring a fluorescent image of the clinical breast specimen to which the fluorescent probe has been applied. [9] A method for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising: (a) applying the fluorescent probe according to any one of [5] to [7] to a clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma; (b) measuring a fluorescent image of a clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma to which the fluorescent probe has been applied.
[10] A fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to any one of [1] to [4] and a GGT activity detection probe.
[11] The fluorescent probe for detecting breast cancer and benign breast tumors according to
[10] , wherein the GGT activity detection probe is a compound represented by the following general formula (II) or a salt thereof: TIFF0007595354000005.tif51153 (in the formula, X is Si(R a )(R b ), Ge(R a )(R b ), Sn(R a )(R b ), C(R a )(R b ), P(=O)(R a ) or O, Here, R a and R b each independently represents a hydrogen atom, an alkyl group, or an aryl group; R 1 represents a hydrogen atom, or 1 to 4 identical or different substituents independently selected from the group consisting of an alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group, and an azide group, each of which may be substituted; R 2 represents a hydrogen atom, a hydroxyl group, a cyano group, an optionally substituted alkyl group, an alkoxy group, an aryl group, or a heteroaryl group; R 3 and R 4 each independently represent 1 to 3 identical or different substituents independently selected from the group consisting of a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted alkyl group, a sulfo group, a carboxyl group, an ester group, an amide group, and an azide group; R 5 , R 6 , and R 7 each independently represents a hydrogen atom or an alkyl group, Here, R 6 or R 7 are R 4 together with may form a ring structure including the nitrogen atom to which they are attached; R 8 represents an acyl residue derived from an amino acid.
[12] A fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to any one of [1] to [4] and a compound represented by the following formula (7) or a salt thereof: TIFF0007595354000006.tif39152
[13] A kit for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to any one of [1] to [4].
[14] A kit for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to any one of [1] to [4] and a GGT activity detection probe.
[15] A kit for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising the fluorescent probe according to any one of [5] to [7]. This provides: Effect of the Invention
[0008] According to the present invention, it is possible to provide a fluorescent probe capable of detecting malignant and benign tumors of the breast. Furthermore, the present invention can provide a fluorescent probe capable of detecting lung adenocarcinoma or lung squamous cell carcinoma. [Brief description of the drawings]
[0009] [Figure 1] Twelve types of glycosidase-reactive fluorescent probes synthesized in the examples. [Diagram 2] 1 shows the results of a screening test of glycosidase-reactive fluorescent probes for the detection of breast cancer and benign breast cancer. [Diagram 3]Evaluation results of the fluorescent probes in breast cancer specimens using glycosidase-reactive fluorescent probes (1, 2, 5, 7, 11, and 12). [Figure 4] Comparison of increased fluorescence in breast cancer and breast fibroadenoma (benign tumor) for glycosidase-reactive fluorescent probes 5 and 11. [Diagram 5] The results of a fluorescence imaging experiment on breast cancer (IDC) using 12 types of glycosidase-reactive fluorescent probes are shown. [Figure 6] The results of a fluorescence imaging experiment on benign tumors (FA) using 12 types of glycosidase-reactive fluorescent probes are shown. [Figure 7] The experimental results of breast tumor imaging using glycosidase-reactive fluorescent probe 5 (HMRef-aD-Man) are shown. [Figure 8] The experimental results of breast tumor imaging using glycosidase-reactive fluorescent probe 5 (HMRef-aD-Man) are shown. [Figure 9] Two-color imaging results using the glycosidase-reactive fluorescent probe 5 and gGlu-2-OMeSiR600 in combination. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] In this specification, unless otherwise specified, an "alkyl group" or an alkyl portion of a substituent containing an alkyl portion (such as an alkoxy group) means, for example, an alkyl group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, and more preferably about 1 to 3 carbon atoms, which is linear, branched, cyclic, or a combination thereof. More specifically, examples of the alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a cyclopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, a cyclopropylmethyl group, an n-pentyl group, and an n-hexyl group.
[0011] In this specification, the term "halogen atom" may refer to any one of a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, and is preferably a fluorine atom, a chlorine atom, or a bromine atom.
[0012] We focused on glycosidase activity in cancer and prepared various fluorescent probes to detect different glycosidase activities, and successfully visualized and evaluated intact glycosidase activities in surgically excised cancer tissues without homogenization by utilizing the prepared fluorescent probes. Specifically, we performed a comprehensive screening of glycosidase activity in human surgical specimens and demonstrated that glycosidase activity differs among tumor types and that certain fluorescent probes are effective for specific imaging of cancer, as described in detail below.
[0013] 1. Breast Cancer Detection Fluorescent Probe One embodiment of the present invention is a fluorescent probe for detecting breast cancer and benign breast tumors, comprising a compound represented by the following general formula (I) or a salt thereof (hereinafter also referred to as "embodiment 1"). TIFF0007595354000007.tif57157
[0014] In general formula (I), R1, if present, represents the same or different monovalent substituents present on the benzene ring. Examples of the monovalent substituents include halogen and optionally substituted alkyl groups.
[0015] m is an integer of 0 to 4. In one preferred aspect of the present invention, m is 0 and R1 does not exist. That is, the benzene ring bonded to the xanthene skeleton is an unsubstituted benzene ring.
[0016] In general formula (I), R2 and R3 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom. When R2 and R3 are alkyl groups, the alkyl group may have one or more halogen atoms, carboxy groups, sulfonyl groups, hydroxyl groups, amino groups, alkoxy groups, etc., and for example, the alkyl group represented by R2 or R3 may be a halogenated alkyl group, a hydroxyalkyl group, a carboxyalkyl group, etc. It is preferable that R2 and R3 are each independently a hydrogen atom or a halogen atom. When R2 and R3 are halogen atoms, it is preferable that R2 and R3 are both fluorine atoms or chlorine atoms. In one preferred aspect of the invention, R2 and R3 are both hydrogen atoms.
[0017] R4 and R5 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom, and are the same as those explained for R2 and R3. It is preferable that R4 and R5 are both hydrogen atoms.
[0018] R6 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or a fluorinated alkyl group having 1 to 5 carbon atoms. The alkyl group of R6 is preferably a methyl group or an ethyl group. The fluorinated alkyl group of R6 is preferably -CH2-CF3 or -CH2-CH2-CF3. In one preferred aspect of the invention, R6 is -CH2-CF3.
[0019] In general formula (I), when present, R7 and R8 each independently represent an alkyl group or an aryl group having 1 to 6 carbon atoms, but R7 and R8 each independently represent an alkyl group having 1 to 3 carbon atoms, and it is more preferable that R7 and R8 are both methyl groups. The alkyl group represented by R7 and R8 may contain one or more halogen atoms, carboxy groups, sulfonyl groups, hydroxyl groups, amino groups, alkoxy groups, etc., and for example, the alkyl group represented by R7 or R8 may be a halogenated alkyl group, a hydroxyalkyl group, a carboxyalkyl group, etc. When R7 or R8 represents an aryl group, the aryl group may be either a monocyclic aromatic group or a condensed aromatic group, and the aryl ring may contain one or more ring-constituting heteroatoms (e.g., nitrogen atom, oxygen atom, sulfur atom, etc.). The aryl group is preferably a phenyl group. One or more substituents may be present on the aryl ring. The substituents may include, for example, one or more halogen atoms, carboxy groups, sulfonyl groups, hydroxyl groups, amino groups, alkoxy groups, etc.
[0020] When X, which will be described later, is an oxygen atom, R7 and R8 do not exist.
[0021] X represents an oxygen atom, a silicon atom or a carbon atom. In one preferred aspect of the invention, X is an oxygen atom.
[0022] n is an integer of 1 to 3, and preferably n is 1.
[0023] In the general formula (I), L is selected from any of the groups represented by the following formulae (1) to (6). TIFF0007595354000008.tif107164
[0024] The fluorescent probe having the group of formula (1) as L is an α-mannosidase-reactive fluorescent probe, the fluorescent probe having the group of formula (2) is an α-L-fucosidase-reactive fluorescent probe, the fluorescent probe having the group of group (3) is an α-hexosaminidase-reactive fluorescent probe, the fluorescent probe having the group of group (4) is an β-N-acetylgalactosaminidase-reactive fluorescent probe, the fluorescent probe having the group of group (5) is an β-glucosidase-reactive fluorescent probe, and the fluorescent probe having the group of group (6) is an β-galactosidase-reactive fluorescent probe. According to the results of the investigations by the present inventors, these fluorescent probes were effective in the image diagnosis of breast fibroadenoma, invasive ductal carcinoma, and non-invasive ductal carcinoma. Therefore, the fluorescent probe of the present invention having any of the groups of formulas (1) to (6) as L is capable of detecting both breast cancer and benign tumors.
[0025] One preferred aspect of embodiment 1 of the present invention is a fluorescent probe for detecting breast cancer and benign breast tumors, comprising a compound represented by the following formula (Ia) or a salt thereof: TIFF0007595354000009.tif40152
[0026] Here, L is selected from any of the groups represented by the following formulas (1) to (6). TIFF0007595354000010.tif104161
[0027] 2. Fluorescent probe for detecting lung cancer or squamous cell carcinoma Another embodiment of the present invention is a fluorescent probe for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising a compound represented by the following general formula (I) or a salt thereof (hereinafter also referred to as "embodiment 2"). TIFF0007595354000011.tif52160
[0028] In general formula (I), R1 to R8, X and n are the same as those explained in the first embodiment.
[0029] In embodiment 2, L is selected from the group of formula (5) or (6): TIFF0007595354000012.tif33153
[0030] The fluorescent probes having a group of formula (5) or (6) as L are β-glucosidase or β-galactosidase reactive fluorescent probes, and the inventors' investigations have shown that these fluorescent probes are effective for specific imaging of major lung cancers including lung adenocarcinoma, in addition to lung squamous cell carcinoma, which could not be detected by aminopeptidase reactive fluorescent probes. Thus, the fluorescent probes of the present invention having a group of formula (5) or (6) as L can specifically detect lung adenocarcinoma or lung squamous cell carcinoma.
[0031] A preferred aspect of the second embodiment of the present invention is a fluorescent probe for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising a compound represented by the following formula (Ia) or a salt thereof: TIFF0007595354000013.tif41157
[0032] Here, L is selected from the group of formula (5) or (6) below. TIFF0007595354000014.tif33154
[0033] The compound represented by the general formula (I) in the embodiments 1 and 2 can exist as an acid addition salt or a base addition salt. Examples of the acid addition salt include mineral acid salts such as hydrochloride, sulfate, and nitrate, and organic acid salts such as methanesulfonate, p-toluenesulfonate, oxalate, citrate, and tartrate. Examples of the base addition salt include metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and organic amine salts such as ammonium salt and triethylamine salt. In addition, salts with amino acids such as glycine may be formed. The compound represented by the general formula (I) or its salt may exist as a hydrate or solvate, and these substances may also be used in the present invention.
[0034] The compound represented by general formula (I) may have one or more asymmetric carbons depending on the type of the substituent. In the present invention, stereoisomers such as optically active substances based on one or more asymmetric carbons and diastereoisomers based on two or more asymmetric carbons, as well as any mixture of stereoisomers, racemates, etc. may be used.
[0035] The methods for producing representative compounds represented by formula (I) are specifically shown in the Examples of this specification. Therefore, a person skilled in the art can produce compounds represented by formula (I) by appropriately selecting reaction raw materials, reaction conditions, reaction reagents, etc. based on these explanations and modifying or altering these methods as necessary.
[0036] 3. Fluorescent probes used in combination with GGT activity detection probes The fluorescent probe of embodiment 1 can be used in combination with a GGT activity detection probe. For example, when detecting breast cancer, if a red GGT probe and the fluorescent probe of embodiment 1 are used in combination, red fluorescence is emitted for both breast cancer (malignant tumor) and benign tumor, whereas the glycosidase-reactive fluorescent probe used in the present invention emits strong green fluorescence, especially for benign tumor. When the images of both are combined, it is possible to image breast cancer tissue in red and benign tumor tissue in yellow. Therefore, by using the glycosidase-reactive fluorescent probe and the GGT probe in combination, it is possible to determine that the site where only the glycosidase-reactive fluorescent probe emits fluorescence is a benign tumor site, and the site where both the glycosidase-reactive fluorescent probe and the GGT probe emit fluorescence is a breast cancer (malignant tumor) site, and it is possible to distinguish between benign tumors and malignant tumors. This makes it possible to improve the efficiency of partial excision surgery without resecting the benign tumor site in surgery.
[0037] That is, another embodiment of the present invention is a fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe of embodiment 1 and a GGT activity detection probe.
[0038] Here, the GGT activity detection probe includes a compound represented by the following general formula (II) or a salt thereof. TIFF0007595354000015.tif50159
[0039] In the general formula (II), X is Si(R a )(R b ), Ge(R a )(R b ), Sn(R a )(R b ), C(R a )(R b ), P(=O)(R a ) or O. Here, R a and R b each independently represents a hydrogen atom, an alkyl group, or an aryl group. R 1represents a hydrogen atom, or 1 to 4 identical or different substituents independently selected from the group consisting of an alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group, and an azide group, each of which may be substituted. R 2 represents a hydrogen atom, a hydroxyl group, a cyano group, an optionally substituted alkyl group, an alkoxy group, an aryl group, or a heteroaryl group. R 3 and R 4 each independently represents 1 to 3 identical or different substituents independently selected from the group consisting of a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted alkyl group, a sulfo group, a carboxyl group, an ester group, an amide group, and an azide group. R 5 , R 6 , and R 7 each independently represents a hydrogen atom or an alkyl group. Here, R 6 or R 7 are R 4 may be taken together to form a ring structure including the nitrogen atom to which they are attached.
[0040] R 8 represents an acyl residue derived from an amino acid. Here, the acyl residue refers to a residue that is a partial structure remaining after removing an OH group from the carboxyl group of an amino acid. That is, the carbonyl portion of the acyl residue derived from an amino acid and R 8 The NH adjacent to forms an amide bond, which connects it to the rhodamine skeleton. The "amino acid" may be any compound having both an amino group and a carboxyl group, including natural and non-natural amino acids. It may be any neutral amino acid, basic amino acid, or acidic amino acid, and may be an amino acid that functions as a transmitter such as a neurotransmitter by itself, or an amino acid that is a component of a polypeptide compound such as a physiologically active peptide (including dipeptides, tripeptides, tetrapeptides, and oligopeptides) or a protein, for example, α-amino acid, β-amino acid, or γ-amino acid. It is preferable to use an optically active amino acid as the amino acid. For example, either D- or L-amino acid may be used for α-amino acid, but it may be preferable to select an optically active amino acid that functions in a living body.
[0041] R 8 is the site of cleavage upon reaction with a target peptidase. The target peptidase can be γ-glutamyltranspeptidase (GGT), dipeptidyl peptidase IV (DPP-IV), or calpain. Thus, when the target peptidase is γ-glutamyltranspeptidase, R 8 is preferably a γ-glutamyl group. When the target peptidase is dipeptidyl peptidase IV, R 8 is preferably an acyl group containing a proline residue. When the target peptidase is calpain, R 8 can be, for example, an acyl group containing a cysteine residue, or Suc-Leu-Leu-Val-Tyr (Suc-LLVY) or AcLM, which are known in the art as calpain substrates. For the principle of fluorescence of the compound represented by general formula (II), see pending Japanese Patent Application No. 2018-210101.
[0042] A preferred embodiment of the present invention is a fluorescent probe according to embodiment 1, 8 is a γ-glutamyl group or a salt thereof.
[0043] Among the compounds represented by the general formula (II), the following compounds can be suitably used. TIFF0007595354000016.tif47152
[0044] The compound represented by the general formula (II) can exist as an acid addition salt or a base addition salt. Examples of the acid addition salt include mineral acid salts such as hydrochloride, sulfate, and nitrate, and organic acid salts such as methanesulfonate, p-toluenesulfonate, oxalate, citrate, and tartrate. Examples of the base addition salt include metal salts such as sodium salt, potassium salt, calcium salt, and magnesium salt, and organic amine salts such as ammonium salt and triethylamine salt. In addition, salts with amino acids such as glycine may be formed. The compound represented by the general formula (II) or its salt may exist as a hydrate or solvate, and these substances may also be used in the present invention.
[0045] The compound represented by general formula (II) may have one or more asymmetric carbons depending on the type of the substituent. In the present invention, stereoisomers such as optically active substances based on one or more asymmetric carbons and diastereoisomers based on two or more asymmetric carbons, as well as any mixture of stereoisomers, racemates, etc. may be used.
[0046] One preferred embodiment of the present invention is a fluorescent probe for detecting breast cancer and benign tumors of the breast, comprising the fluorescent probe of embodiment 1 and a compound of formula (7) or a salt thereof.
[0047] 4. Kit for detecting breast cancer and benign breast tumors using the fluorescent probe of the present invention Another embodiment of the present invention is a kit for detecting breast cancer and benign tumors of the mammary gland, comprising the fluorescent probe of embodiment 1. Another embodiment of the present invention is a kit for detecting breast cancer and benign breast tumors, comprising the fluorescent probe of embodiment 1 and a GGT activity detection probe. The GGT activity detection probe is as described above. Another embodiment of the present invention is a kit for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising the fluorescent probe of embodiment 2.
[0048] In the kit, the fluorescent probe of the present invention is usually prepared as a solution, but it may also be provided as a composition in an appropriate form such as a powder mixture, a lyophilized product, granules, tablets, or liquid, and can be applied by dissolving it in distilled water for injection or an appropriate buffer solution at the time of use.
[0049] The kit may also contain other reagents, etc., as necessary. For example, additives such as solubilizing agents, pH regulators, buffers, and isotonicity agents can be used, and the amounts of these additives can be appropriately selected by those skilled in the art.
[0050] Another embodiment of the present invention is a method for detecting breast cancer and benign tumors of the breast, comprising the steps of: (a) applying the fluorescent probe of embodiment 1 to a clinical breast specimen; and (b) measuring a fluorescent image of the clinical breast specimen to which the fluorescent probe has been applied. The application of the fluorescent probe to the breast clinical specimen in step (a) can be carried out, for example, by locally spraying a solution of the fluorescent probe onto the breast clinical specimen.
[0051] Another embodiment of the present invention is a method for detecting lung adenocarcinoma or lung squamous cell carcinoma, comprising the steps of (a) applying the fluorescent probe of embodiment 2 to a clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma, and (b) measuring a fluorescent image of the clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma to which the fluorescent probe has been applied. In step (a), the fluorescent probe can be applied to a clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma by, for example, locally spraying a solution of the fluorescent probe onto the clinical specimen of lung adenocarcinoma or lung squamous cell carcinoma. EXAMPLES
[0052] The present invention will be described below with reference to examples, but the present invention is not limited thereto.
[0053] [Synthesis Example 1] Synthesis of probe 1 (β-glucosidase reactive probe) HMRef (0.426 g, 1.07 mmol), 2,3,4,6-tetra-O-acetyl α-D-glucopyranosyl bromide (8.26 g, 20.1 mmol), Ag2O (4.71 g, 20.3 mmol), and Na2SO4 (720 mg, 2.00 mmol) were dissolved in 30 mL of acetonitrile (ultra-dehydrated) and stirred at room temperature for 24 hours. The reaction solution was filtered through Celite, the filtrate was collected, and the acetonitrile was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=95:5) to obtain an acetylated glycoadduct. This was dissolved in methanol, and a solution of NaOMe (520 mg, 9.63 mmol) dissolved in 5 mL of methanol was added, and the mixture was stirred at room temperature for 5 hours. The reaction solution was neutralized with Amberlite IR 120, and the methanol was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=90:10) to obtain the desired product (301 mg, 0.535 mmol) in a yield of 50.2%.
[0054] [Synthesis Example 2] Synthesis of probe 5 (α-mannosidase reactive probe) HMRef (96.0 mg, 0.24 mmol), penta-O-acetyl-D-mannopyranoside (3.33 g, 8.53 mmol), boron trifluoride diethyl ether complex (8.0 mL, 63.4 mmol), and Na2SO4 (500 mg, 3.34 mmol) were dissolved in 15 mL of dichloromethane and stirred for 24 hours. The reaction solution was filtered through Celite, and the dichloromethane layer was extracted by a separation operation using 1 M NaOH and removed under reduced pressure. The residue was dissolved in 15 mL of methanol, and a solution of NaOMe (1.60 g, 29.6 mmol) dissolved in 5 mL of methanol was added and stirred at room temperature for 5 hours. The reaction solution was neutralized with Amberlite IR 120, and methanol was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=90:10) to obtain a crude product. This was further purified by HPLC (5-80% MeCN in water (0.1% TFA) over 90 min) to obtain the desired product (61.6 mg, 0.200 mmol) in a yield of 45.6%.
[0055] [Synthesis Example 3] Synthesis of probe 7 (α-L-fucosidase reactive probe) HMRef (90.0 mg, 0.226 mmol), 2,3,4-Tri-O-acetyl-L-fucopyranosyl trichloroacetimidate (862 mg, 1.99 mmol), and TMSOTf (442 mg, 1.99 mmol) were dissolved in 10 mL of dichloromethane and stirred at -41°C for 12 hours. The reaction solution was diluted with dichloromethane and neutralized with saturated aqueous sodium bicarbonate. The organic layer was extracted by liquid separation and removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=95:5) to obtain an intermediate. This was dissolved in 5 mL of methanol, and a solution of NaOMe (1.33 g, 24.6 mmol) dissolved in 5 mL of methanol was added and stirred at room temperature for 5 hours. The reaction solution was neutralized with Amberlite IR 120 and methanol was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=95:5) to give a crude product, which was further purified by HPLC (5-80% MeCN in water (0.1% TFA) over 90 min) to give the desired product (14.4 mg, 0.0257 mmol) in a yield of 11.7%.
[0056] [Synthesis Example 4] Synthesis of probe 12 (β-N-acetylgalactosaminidase reactive probe) HMRef (46.7 mg, 0.117 mmol), 2-acetoamide-3,4,6-tri-O-acetyl-2-deoxy-aD-galactopyranosyl chloride (400 mg, 1.09 mmol), Ag2O (400 mg, 1.72 mmol), NaI (88.3 mg, 0.589 mmol) and Na2SO4 (500 mg, 3.34 mmol) were dissolved in 10 mL of acetonitrile (ultra-dehydrated) and stirred at room temperature for 24 hours. The reaction solution was filtered through Celite, the filtrate was collected, and the acetonitrile was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=95:5) to obtain an acetylated glycoadduct. This was dissolved in methanol, and a solution of NaOMe (0.50 g, 9.25 mmol) dissolved in 5 mL of methanol was added, and the mixture was stirred at room temperature for 5 hours. The reaction solution was neutralized with Amberlite IR 120, and methanol was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH2Cl2:MeOH=90:10) to obtain a crude product. This was further purified by HPLC (5-80% MeCN in water (0.1% TFA) over 90 min) to obtain the target product (11.3 mg, 0.0216 mmol) in a yield of 28.2%.
[0057] Probe 2 was synthesized according to the description in Matsuzaki, H et al., Bioconju. Chem., 27(4), 973-981 (2016), and probe 11 was synthesized according to the description in Asanuma, D et al., Nat. Commun., 6, 6463 (2015). Probes 3, 4, 6, 8, 9, and 10 were synthesized in the same manner as the above probes.
[0058] [Example 1] Screening of glycosidase-reactive fluorescent probes for detection of breast cancer and benign breast cancer. Using the 12 types of glycosidase-reactive fluorescent probes synthesized above (see FIG. 1), screening for the detection of breast cancer and benign disease was carried out as follows. 200μL of 50μM PBS solution of each fluorescent probe was added to each well containing a clinical breast specimen, and fluorescence images at 540nm were acquired at 1, 3, 5, 10, 20, and 30 minutes using a Maestro in vivo imaging system (PerkinElmer). Regions of Interest (ROIs) were created on the Maestro software, and the fluorescence intensity values were quantified and compared. Filter settings were Ex / Em=465-30nm / 515nm long-pass.
[0059] The results are shown in Figure 2. FIG. 2A shows the results of screening the fluorescent probe using surgically excised human breast specimens.
[0060] Panel b of Figure 2 shows the increase in fluorescence at 30 min in breast FA tissue in the presence and absence of each inhibitor. Black bars represent the increase in fluorescence in the absence of inhibitors, and grey bars represent the increase in fluorescence in the presence of inhibitors. Fluorescent probe concentration = 50 μM, inhibitor concentration = 500 μM.
[0061] Figure 2c shows the results of a comprehensive analysis of intact glycosidase activity in normal breast, IDC (breast cancer) and FA (benign tumor) tissues using 12 types of fluorescent probes. The increase in fluorescence represents the increase from 1 to 30 minutes after the addition of the fluorescent probe. Each dot represents the increase in fluorescence in normal breast, IDC, DCIS and FA tissues, from left to right. From Figure 3c, glycosidase-reactive fluorescent probes 1, 2, 5, 7, 11 and 12 showed an increase in fluorescence for both breast cancer and FA (benign tumor) tissues.
[0062] Panel D of Figure 2 shows the results of immunohistochemical analysis of normal mammary gland, FA or IDC tissues for MAN2C1. If no stained cells were found, the tissues were scored as negative, otherwise they were scored as positive. As a result, we confirmed stronger staining in FA and IDC tissues than in normal tissues, confirming the overexpression of MAN2C1 in these tissues.
[0063] Figure 2e shows the results of the DEG assay. The DEG assay was performed according to the procedure described in J. Am. Chem. Soc., 135, 6002-6005 (2013). In the FA tissue, a DEG assay was performed using the α-mannosidase-reactive probe 5, and only one fluorescent spot was observed by two-dimensional electrophoresis, from which MAN2C1 was identified by peptide mass fingerprinting. In addition, only one similar fluorescent spot was confirmed by two-dimensional electrophoresis in the IDC tissue. These results indicate that MAN2C1 is the enzyme responsible for the increase in fluorescence of the α-mannosidase-reactive probe 5.
[0064] Six glycosidase-reactive fluorescent probes (1, 2, 5, 7, 11, and 12) that showed increased fluorescence in Figure 2c were evaluated in breast cancer specimens. Four cases of IDC breast cancer and one case of DCIS were used as specimens, and the fluorescent probe concentration was 50 μM. The results are shown in Figure 3. Figure 3 confirms that glycosidase-reactive fluorescent probes 5 and 11 showed a large increase in fluorescence and a large fluorescence intensity ratio between tumor and normal tissues.
[0065] The increase in fluorescence in breast cancer and benign tumors was compared for the glycosidase-reactive fluorescent probes 5 (HMRef-α-D-Man) and 11 (HMRef-β-D-GlcNAc) (fluorescent probe concentration = 50 μM) in Figure 4. 200μL of the above-mentioned concentration of fluorescent probe in PBS solution was added to each well containing the clinical breast specimen, and fluorescence images at 540nm were acquired at 1, 3, 5, 10, 20, and 30 minutes using the Maestro in vivo imaging system (PerkinElmer). Each fluorescence intensity value was quantified and compared by taking Regions Of Interest (ROIs) on the Maestro software. Filter settings were Ex / Em=465-30nm / 515nm long-pass.
[0066] As a result, glycosidase-reactive fluorescent probes 5 (HMRef-α-D-Man) and 11 (HMRef-β-D-GlcNAc) showed a higher increase in fluorescence in tumor tissues than in normal breast tissues (Normal), and also showed higher fluorescence in benign tumor tissues (FA) than in cancer tissues (IDC, DCIS). These results suggest that both probes may be useful for breast cancer fluorescence imaging or specific detection of benign tumors.
[0067] In addition, imaging images of the time change in fluorescence increase for breast cancer (IDC) and benign tumor (FA) using 12 types of glycosidase-reactive fluorescent probes are shown in Figures 5 to 6. The experiment was carried out under the following conditions. 200 mL of the above-mentioned PBS solution of the fluorescent probe was added to each well containing the clinical breast specimen, and fluorescence images at 540 nm were obtained at 1, 3, 5, 10, 20, and 30 minutes using the Maestro in vivo imaging system (PerkinElmer). Regions of Interest (ROIs) were created on the Maestro software, and the fluorescence intensity values were quantified and compared. Filter settings were Ex / Em=465-30nm / 515nm long-pass. Figure 5 shows the results of fluorescence imaging using breast cancer tissue (right), and Figure 6 shows the results of fluorescence imaging using a benign tumor (FA) (right).
[0068] [Example 2] Breast tumor imaging using HMRef-aD-Man Imaging was performed under the following conditions using the glycosidase-reactive fluorescent probe 5 (HMRef-aD-Man) (concentration: 50 mM). 3mL of the fluorescent probe in PBS at the above concentration was added to a dish containing a clinical breast specimen (a specimen containing a mixture of normal and tumorous areas), and fluorescent images were taken at each time point. Below, fluorescent images of clinical specimens of DCIS and FA were taken using the Maestro in vivo imaging system (PerkinElmer). Filter settings for each were Ex / Em=465-30nm / 515nm long-pass. Fluorescent images of clinical specimens of IDC were taken using a homme-made portable imaging device equivalent to the Maestro in vivo imaging system.
[0069] The results are shown in Figures 7 and 8. FIG. 7A shows the imaging results of a surgically resected IDC (breast cancer). Approximately 20 minutes after the probe was sprayed, only the IDC site was visualized with strong fluorescence.
[0070] Figure 7b shows the results of histological analysis and immunostaining of MAN2C1 for the above specimens. It was confirmed that the areas where increased fluorescence was confirmed were the same as the areas that were histologically identified as IDC and the areas where MAN2C1 was highly expressed. Figure 7c shows the imaging results of DCIS (breast cancer) that had been surgically removed. After the probe was dispersed, only the DCIS site was visualized with strong fluorescence within 15 minutes.
[0071] Figure 7d shows an example of the Regions of Interest (ROIs) of the above specimen, the results of histological analysis, and the results of immunostaining for MAN2C1. It was confirmed that the areas where increased fluorescence was confirmed corresponded to the areas that were histologically DCIS and the areas where MAN2C1 was highly expressed. In addition, the detection of extremely small DCIS tissues of less than 1 mm was also confirmed.
[0072] Figure 7e shows the increase in fluorescence at 15 minutes in the Regions of Interest (ROIs) of the above specimen. No significant increase in fluorescence was observed in the histologically normal areas, but a significant increase in fluorescence was observed in the histologically DCIS areas.
[0073] Figure 8(a) shows the imaging results of a surgically removed FA (benign tumor). After the probe was dispersed, only the FA site was visualized with strong fluorescence within 10 minutes.
[0074] Figure 8b shows the results of histological analysis and immunostaining of MAN2C1 for the above specimens. It was confirmed that the areas where increased fluorescence was confirmed corresponded to the areas that were histologically FA and areas where MAN2C1 was highly expressed.
[0075] [Example 3] Distinguishing benign tumors from breast cancer using HMRef-α-D-Man and GGT probes in combination Two-color imaging was performed using the glycosidase-reactive fluorescent probe 5 (HMRef-α-D-Man) (concentration: 50 μM) and the GGT probe gGlu-2-OMeSiR600 (concentration: 50 μM) under the following conditions. 200μL of the above-mentioned PBS solution of the fluorescent probe was added to each well containing the clinical breast specimen, and fluorescence images at 540nm and 640nm were acquired at 1, 3, 5, 10, 20, and 30 minutes using the Maestro in vivo imaging system (PerkinElmer). Each fluorescence intensity value was quantified and compared by taking Regions of Interest (ROIs) on the Maestro software. For the glycosidase-reactive fluorescent probe 5, the filter settings were Ex / Em=465-30nm / 515nm long-pass. For the GGT probe, the filter settings were Ex / Em=570-40nm / 610nm long-pass.
[0076] The results are shown in Figure 9. Figure 9a shows a fluorescence image at 540 nm and a pseudo-real color image at 500-720 nm. Figure 9b shows a fluorescence image at 640 nm and a pseudo-real color image at 600-820 nm. The exposure times (in milliseconds) of the fluorescence images are shown at the bottom of each image. Figure 9c shows the composite images of green and red fluorescent images 30 min after administration of both probes into breast cancer and benign tumor tissues. The exposure times are 40 ms for the green image and 20 ms for the red image. Figure 9d shows a comparison of the composite images at each time point. As shown in Fig. 9c, the glycosidase-reactive fluorescent probe 5 emitted green fluorescence for benign tumors, whereas the red GGT probe gGlu-2OME-SiR600 emitted red fluorescence for both breast cancer (malignant tumor) and benign tumors. When the images of both were combined, breast cancer tissues could be imaged in red and benign tumor tissues in yellow. Therefore, by using the glycosidase-reactive fluorescent probe and the GGT probe in combination, it is possible to determine that the area where only the glycosidase-reactive fluorescent probe emits fluorescence is a benign tumor area, and the area where both the glycosidase-reactive fluorescent probe and the GGT probe emit fluorescence is a breast cancer (malignant tumor) area, making it possible to distinguish between benign and malignant tumors. This makes it possible to improve the efficiency of partial excision surgery without resecting the benign tumor area in surgery.
Claims
1. A fluorescent probe for detecting breast cancer and benign breast tumors, comprising a compound represented by the following general formula (I) or a salt thereof, the fluorescent probe exhibiting higher fluorescence in benign tumor tissue than in cancer tissue: (In the formula, R 1 represent, if present, identical or different monovalent substituents present on the benzene ring; R 2 and R 3 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R 4 and R 5 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a halogen atom; R 6 represents a fluorinated alkyl group having 1 to 5 carbon atoms; R 7 and R 8 does not exist; X represents an oxygen atom; n is 1; L is a group of the following formula (1):
2. A fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to claim 1 and a GGT activity detection probe.
3. A method for assisting in the detection of breast cancer and benign tumors of the breast, comprising the steps of: (a) applying a fluorescent probe according to any one of claims 1 to 2 to a clinical breast specimen; and (b) measuring a fluorescent image of the clinical breast specimen to which the fluorescent probe has been applied.
4. 3. The fluorescent probe for detecting breast cancer and benign breast tumors according to claim 2, wherein the GGT activity detection probe is a compound represented by the following general formula (II) or a salt thereof: (In the formula, X is Si(R a ) (R b ), Ge(R a ) (R b ), Sn(R a ) (R b ), C(R a ) (R b ), P(=O)(R a ) or O, Here, Ra and Rb each independently represent a hydrogen atom, an alkyl group, or an aryl group; R 1 represents a hydrogen atom or 1 to 4 identical or different substituents independently selected from the group consisting of an alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group, and an azide group, each of which may be substituted; R 2 represents a hydrogen atom, a hydroxyl group, a cyano group, an optionally substituted alkyl group, an alkoxy group, an aryl group, or a heteroaryl group; R 3 and R 4 each independently represents 1 to 3 identical or different substituents independently selected from the group consisting of a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted alkyl group, a sulfo group, a carboxyl group, an ester group, an amide group, and an azide group; R 5 , R 6 , and R 7 each independently represents a hydrogen atom or an alkyl group, Here, R 6 Or R 7 are R 4 may together form a ring structure including the nitrogen atom to which they are attached; R 8 represents an acyl residue derived from an amino acid.)
5. A fluorescent probe for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to claim 1 and a compound represented by the following formula (7) or a salt thereof:
6. A kit for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to claim 1.
7. A kit for detecting breast cancer and benign breast tumors, comprising the fluorescent probe according to claim 1 and a GGT activity detection probe.
Citation Information
Patent Citations
Enzyme-specific intracellular-retentive red fluorescent probe
JP2018000074A
Near-infrared fluorescent probe for peptidase activity detection
JP2018140971A
ASYMMETRICAL Si RHODAMINE AND RHODOL SYNTHESIS
WO2014106957A1
Enzyme-specific fluorescent compound capable of being retained in cells
WO2015174460A1
